• TPCA-1: A Practical IKK-2 Inhibitor Workflow

  2026-09-02

  TPCA-1 provides a selective way to perturb IKK-2 and connect NF-κB activation with cytokine release, apoptosis, and autophagy readouts. This workflow shows how to move from monocyte or proximal-tubule cell assays to mechanism-focused inflammation research while avoiding common solubility, vehicle, and endpoint errors.

• (S)-(+)-Methoprene: Juvenile Hormone Signaling

  2026-09-01

  (S)-(+)-Methoprene is a juvenile hormone analog that activates the insect receptor Methoprene-tolerant and helps maintain stage-specific developmental programs. Its defined formula, solvent compatibility, and arthropod-selective biology make it useful for hormone-regulated development, metamorphosis, reproduction, and receptor-ligand studies.

• EZ Cap™ Firefly Luciferase mRNA for Assays

  2026-09-01

  EZ Cap™ Firefly Luciferase mRNA provides a practical positive-control payload for transfection, translation, gene regulation, viability, and imaging studies. Its Cap1 structure and optimized poly(A) tail support robust reporter expression while enabling systematic comparison of delivery formulations and cell-based workflows.

• Temozolomide: ATRX-Aware Assay Design

  2026-08-31

  Temozolomide is a small-molecule alkylating agent whose effects depend on DNA damage processing and tumor genotype. This guide translates ATRX-focused glioma evidence into a practical framework for designing, controlling, and interpreting combination assays.

• Caspase-3/7 Inhibitor I: Lab Scenarios

  2026-08-30

  A scenario-based guide to using Caspase-3/7 Inhibitor I (SKU A1925) for apoptosis pathway dissection, viability assays, and caspase activity measurement. It explains selectivity, solvent handling, dose interpretation, and practical vendor-selection criteria for more defensible cell-death experiments.

• α-Bungarotoxin: Mapping α7 Receptor Causality

  2026-08-29

  α-Bungarotoxin enables precise nicotinic receptor blockade for testing α7 nAChR-dependent signaling. This article explains how its use in pyridostigmine-treated placental ischemia models strengthens causal assay design beyond simple pathway observation.

• HyperScript III RT SuperMix for CRC qPCR

  2026-08-29

  Translate bile acid metabolism signatures into reproducible CRC biomarker assays with high-yield cDNA synthesis, integrated genomic DNA contamination removal, and support for difficult RNA templates. The workflow is designed for low-abundance, high-GC, and low-copy transcripts measured by SYBR Green or probe-based qPCR.

• Cy5-UTP (Cyanine 5-UTP) Workflow Guide

  2026-08-28

  Learn how Cy5-UTP (Cyanine 5-UTP), SKU B8333, can strengthen RNA probe synthesis, fluorescence in situ hybridization, and fluorescence-assisted cell assay workflows. This scenario-based guide separates RNA labeling from viability measurement and provides practical guidance on compatibility, optimization, interpretation, and vendor selection.

• Protein A/G Magnetic Co-IP/IP Kit Workflow

  2026-08-28

  Turn antibody-based capture into a reproducible workflow for protein complex isolation, ubiquitination studies, and antibody purification. The Protein A/G Magnetic Co-IP/IP Kit combines Fc region antibody binding with rapid magnetic separation for downstream SDS-PAGE or mass spectrometry.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-08-27

  Fabi and Malaguti’s 2013 review evaluated palonosetron hydrochloride as a long-acting 5-HT3 receptor antagonist for preventing radio- and chemotherapy-induced nausea and vomiting. Its central contribution was to clarify why high receptor affinity and prolonged half-life may improve delayed control, particularly after moderately emetogenic chemotherapy, while identifying unresolved needs in multi-day treatment and combination antiemetic therapy.

• BIRC2 and BIRC3 Regulation in Pulmonary Epithelium

  2026-08-27

  Thorne et al. define distinct responses of BIRC2 and BIRC3 to inflammatory cytokines and glucocorticoids in pulmonary epithelial models. Their multi-model design shows that BIRC3 is strongly inducible and potentially protective, whereas BIRC2 is comparatively constitutive, providing a framework for interpreting epithelial inflammatory signaling and cell-death resistance.

• Guanabenz Acetate: A Layered Assay Strategy

  2026-08-26

  Guanabenz Acetate enables a layered approach to α2-adrenergic receptor pharmacology, separating receptor-proximal signaling from stress-granule and innate-immune phenotypes. This article translates recent GADD34–IRF3 findings into practical, hypothesis-driven assay decisions.

• Drug Response Metrics in Cancer In Vitro

  2026-08-26

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these measurements capture different relationships between proliferative arrest and cell death. The framework supports more informative in vitro drug-response experiments by requiring researchers to interpret growth inhibition and killing as related but noninterchangeable outcomes.

• PexRAP Links Ether Lipids to B-Cell Immunity

  2026-08-25

  Cho and colleagues show that B-lineage expression of the ether-lipid biosynthesis enzyme PexRAP, encoded by Dhrs7b, supports B-cell survival, germinal center development, antibody production, and affinity maturation. By combining inducible mouse genetics, imaging mass spectrometry, immunization, and mechanistic cell assays, the study connects cell-intrinsic lipid metabolism with the quality of humoral immunity.

• Amikacin Sulfate: NTM Assay Workflows

  2026-08-25

  Build stronger non-tuberculous mycobacterial studies by connecting extracellular CFU testing, intracellular dendritic-cell assays, and granuloma-level pharmacology. This workflow also adapts the functional-selection logic of a Cas9 inhibitor discovery study without confusing a metagenomic screening principle with antibiotic evidence.

452 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page